The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas [PDF]
Frontiers in Endocrinology, 2019 Dopamine agonists such as bromocriptine and cabergoline are the predominant treatment drugs for prolactinoma by inhibiting prolactin secretion and shrinking tumor size.
Xiaoshuang Liu +6 more
doaj +6 more sources
Dopamine Agonists for Pituitary Adenomas [PDF]
Frontiers in Endocrinology, 2018 Dopamine agonists (DA) are well established as first-line therapy for prolactinomas. These tumors express high levels of dopamine 2 receptors (D2R), leading to the strong efficacy of DA in reducing tumor size and hormonal secretion. Other pituitary tumor
Odelia Cooper, Yona Greenman
doaj +5 more sources
Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment [PDF]
Clinical Parkinsonism & Related Disorders, 2023 Dopamine agonists (DAs) have demonstrated efficacy for the treatment of Parkinson’s disease (PD) but are limited by adverse effects (AEs). DAs can vary considerably in their receptor subtype selectivity and affinity, chemical composition, receptor ...
Stuart H. Isaacson +4 more
doaj +2 more sources
Time until Need for Levodopa among New Users of Dopamine Agonists or MAO-B Inhibitors [PDF]
Parkinson's Disease, 2021 Objective. To investigate the use of dopamine agonists and monoamine oxidase type B (MAO-B) inhibitors in the Norwegian population, between 1 July 2006 and 31 December 2016.
Caroline D. Binde +2 more
doaj +2 more sources
Experience with Dopamine Agonists in the Treatment of Prolactinomas [PDF]
Acta Medica Lituanica, 2022 The article is devoted to the conservative treatment of hyperprolactinemia of tumor origin. Cabergoline is considered as an effective treatment not only for microadenomas but also for large pituitary tumors which is illustrated by the clinical case of ...
Nadiya Barabash, Tetiana M. Tykhonova
doaj +2 more sources
Macroprolactinoma with secondary resistance to dopamine agonists: a case report and review of the literature [PDF]
Journal of Medical Case Reports, 2023 Background Resistance to dopamine agonists is not uncommonly seen in prolactinomas. However, development of resistance to dopamine agonists after an initial period of robust treatment response is rare, and only 39 cases have been reported in the past ...
Eng-Loon Tng +2 more
doaj +2 more sources
Impact of behavioral side effects on the management of Parkinson patients treated with dopamine agonists [PDF]
Clinical Parkinsonism & Related Disorders, 2021 Dopamine agonists are one of the main stay of treatment option for Parkinson disease (PD). Side effects that develop from their use are generally categorized into behavioral and non-behavioral.
Mohammad Edrees Mohammad +6 more
doaj +2 more sources
Impulse control disorders and use of dopamine agonists in early onset Parkinson’s disease [PDF]
Frontiers in NeurologyIntroductionImpulse control disorders (ICDs) are defined as excessive and repetitive behaviors that may affect Parkinson’s disease (PD) patients exposed to dopamine agonists. Current data on ICDs in patients with early-onset Parkinson’s disease (EOPD) is
Pierpaolo Turcano +8 more
doaj +2 more sources
Impulse control disorders and dopamine agonists [PDF]
European Psychiatry, 2021 Introduction Impulse control disorders (ICDs) are an adverse effect of dopamine agonists (DAAs) that affects the quality of life and can lead to legal, criminal and familiar problems.
D. Martins +3 more
doaj +2 more sources
Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report [PDF]
European Psychiatry, 2022 Introduction We present the case of a 65-year-old woman with multiple and chronic psychosomatic symptoms. Due to motor impairments she was diagnosed in 2009 with Parkinson’s Disease (PD) by the neurology department and empirical treatment with levodopa ...
M.L. Costa, A. Cerame
doaj +2 more sources